thoracic_oncol

[Dana-Farber @DanaFarber]

A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer.

In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy.

While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers.

As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.”

Congratulations to the researchers and patients who made this important progress possible. 👏👏👏

Video Courtesy: @asco

[thoracic_oncol @ThoracicOnc]

@ikechannazo 私も電車を止められず、1ヶ月くらい詰まってます！何かヒントいただけませんでしょうか😭

[Kent 👃 耳鼻科医 │ 経鼻内視鏡・頭頸部外科 @minaniyasashiku]

学会���加前にすることのお勧めは抄録集全読み。
全部読むと、いまのtopicがよくわかる。
わぃはPDFをiPadProにいれて、マーカーやメモをとりながら、聞きにいきたい演題にはしおりをつけている。
実際の学会参加した際は、このPDF上に追加でメモを取る（この際マーカーの色を変えると良い）。
結構時間かかるけど、お勧めです（今日、6時間かけてさっき読みきりました）

PS：前耳鼻咽喉科頭頸部外科学会理事長が、自らのCPA後蝶形骨洞炎の治療体験をオーラル発表するようなので、会員は拝聴必須です❗

[Science News @SciencNews]

10 tips on how we write papers @Matter_CP

#PhD #PhDlife #academics #AcademicChatter #AcademicTwitter #Postdocs #Research #Science

[Aakash Desai @ADesaiMD]

LAURA Ph 3: Osimertinib vs Placebo #ASCO24 @ASCO

➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️
➡️ 24-mo PFS: 65% vs 13% 📈
➡️ 81% received osi at progression 💊, Good!
➡️AE discontinuation**: 13% vs 5% ⚠️

Can't wait for @RamalingamMD's presentation today! 🎤 #ASCO24 @OncoAlert Data courtesy: @FordePatrick’s tweet! @OncoAlert